Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Medical Devices

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Comment by elgin1on Jan 26, 2020 9:04pm

76 Views

Post# 30601046

RE:in-eligible One ;) Think Harder Please ;)

jwallisca wrote: in-eligible One ;)

Proactive vs reactive... OR is there another reason?

My take is this is being done for a reason "company strategy" for the FDA Trial only comes to mind because it is definitely systematic rather than random. Other matters like changes in CFO and anything involving hemophilia and thyroid are news released pronto.

Waiting and hoping for something decent on the FDA Trial soon(ish?).

jwall

investors just want information period. They want to know how trial is proceeding, cash burn rate, collaborations. Nobody knows the company strategy, Ii don’t think even management knows it. We can’t assume anything, periodic updates were promised but nothing delivered. What investors fear is that the trial is dragging longer than anticipated and so are costs . Don’t want another surprise financing. Share price speaks volume to what market interprets is going on. Until we have definitive news on results or collaboration, everything else is just hear say.

Btw when was the last time they released a pronto nr on Thyroid or Hemophilia anyways ?

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features